Misonix Incorporated Announces New GPO Agreement With First Choice Cooperative

FARMINGDALE, N.Y., Aug. 18 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art ultrasonic medical device technology, which worldwide is used for acute health conditions, has entered into a new, 3-year Group Purchasing Organization (“GPO”) Agreement with First Choice Cooperative (“FCC”), headquartered in Tyler, Texas. Under the terms of the agreement, Misonix will offer FCC members the opportunity to purchase the SonaStar® Ultrasonic Surgical Aspiration System and the SonicOne® Ultrasonic Wound Care System. The agreement is a sole source award, meaning that no competitive products that feature similar technology are available to FCC members.

FCC has 635 Acute Care and Clinic members located throughout the United States, with a concentration in the Southwest. FCC prides themselves on high contract compliance within their membership group.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while preserving surrounding healthy tissue. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

“We are extremely pleased that FCC has added two core Misonix products to the portfolio offered to their buying group,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “Their commitment to expanding their purchasing network and the contract loyalty they inspire within their membership are attributes that we seek in GPO partners.”

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.